A large pharmaceutical company was running a complex antibiotic study for a treatment targeting complicated intra-abdominal infection (cIAI). Based on extensive experience with facilitating and executing these complex antibiotic studies, Labcorp Drug Development was selected to support this Phase IIb trial.

We serve as an extension of your team, working seamlessly to bring together the right expertise, technology, data and processes for your dermatology study. We're more than a global contract research organization -- we know how to anticipate your needs and create value for your medical and cosmetic program.

A small biotech company worked with Labcorp Drug Development starting with clinical pharmacology and Phase Ia/IIb studies to determine the best path forward for their molecules targeting Type 1 diabetes.

Obtaining approval from several regulatory agencies around the world requires a coordinated effort and a strategic partnership.

A large pharmaceutical company chose Labcorp Drug Development to support its ongoing Phase II study evaluating patients with cUTI.

A small biopharmaceutical company, developing a novel therapeutic platform, engaged Labcorp Drug Development to set up and conduct a global, Phase III, pivotal clinical trial on a promising treatment for a rare genetic cardiovascular disease.

A small-to mid-size pharmaceutical company in India was developing a new combination treatement for complicated urinary tract infection. They were starting studies in the U.S. and EU but also wanted to evaluate their treatment in China with a Phase III trial.

Labcorp's Clinical Trial Management Systems (CTMS) act as a central repository for operational data, supports streamlining operations and enables the detection of project plan variances and identification of potential problems.

Labcorp Drug Development's Market Access Consulting team can advise and provide support in the design, development and implementation of your digital transformation needs in market access, starting with an initial needs assessment and a recommendation of how best to make use of available digital technologies to bolster and support successful execution of y

This article explores the field of NH studies, explaining what they are and how they can be used to build faster, more efficient, patient-centric trials with a better chance of success and approval, both for rare diseases and the wider drug development market.